European Commission Approves Vocabria + Rekambys for HIV Treatment in Adolescents Aged 12 and Older

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

February 03, 2025 | Monday | News
Merck's CAPVAXIVE™ Pneumococcal Vaccine Receives Positive CHMP Recommendation for Approval in the European Union

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced  that the Committee for Medicinal Products for Human Use (CHMP) of ...

February 03, 2025 | Monday | News
Amgen Announces European Commission Approval of BLINCYTO® for Frontline Treatment of B-ALL

Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...

January 31, 2025 | Friday | News
GSK's Depemokimab Accepted for EMA Review in Asthma and Chronic Rhinosinusitis with Nasal Polyps

GSK plc (LSE/NYSE: GSK) announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemok...

January 29, 2025 | Wednesday | News
Roche Announces Positive Overall Survival Results for Itovebi™ in Advanced Breast Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...

January 29, 2025 | Wednesday | News
Upperton Pharma Solutions Expands with New Sterile Manufacturing Facility in Nottingham

Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing...

January 28, 2025 | Tuesday | News
European Commission Approves LAZCLUZE® (lazertinib) and RYBREVANT® (amivantamab) for First-Line Treatment of EGFR-Mutant Advanced NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...

January 28, 2025 | Tuesday | News
Roche Reports Positive Two-Year Results from EMBARK Trial for Elevidys™, First Gene Therapy for Duchenne Muscular Dystrophy

Roche announced  positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (de...

January 28, 2025 | Tuesday | News
Swiss Business Hub India Strengthens Swiss-Indian Ties at World Economic Forum 2025 in Davos

The Swiss Business Hub India once again played a pivotal role at the sidelines of the World Economic Forum 2025 in Davos, fostering connections between s...

January 27, 2025 | Monday | News
Norgine and X4 Pharmaceuticals Celebrate EMA Validation of Mavorixafor for WHIM Syndrome

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 that their Marketing Authorization Applicatio...

January 27, 2025 | Monday | News
Bristol Myers Squibb Reports Significant Progression-Free Survival Benefit for Opdivo® Plus Yervoy® in MSI-H/dMMR Metastatic Colorectal Cancer

Bristol Myers Squibb (NYSE: BMY) announced results of an analysis from the three-arm Phase 3 CheckMate -8HW trial evaluating Opdivo® (ni...

January 27, 2025 | Monday | News
Merck and Eisai Announce Promising Interim Results from LEAP-015 Trial of KEYTRUDA® and LENVIMA® in HER2-Negative Gastroesophageal Adenocarcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...

January 27, 2025 | Monday | News
Biogen's Higher Dose Regimen of Nusinersen for SMA Receives FDA and EMA Review

Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Applicati...

January 24, 2025 | Friday | News
EU Approves Sarclisa in Combination with VRd for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

January 23, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close